english.prescrire.org > Prescrire International > N°129 - July 2012

n°129

July 2012

Issue Contents
Editorial

Free  Early signals

p.172
Hasty regulators gambled on aliskiren's harms and benefits

New Products


Belatacept (New Drug)

p.173-176
In kidney transplantation: more risky than ciclosporin

INN common stem: -piprazole

p.176

Aliskiren: negative trial data (Harms)

p.176
A do-not-use drug

Flurbiprofen without a prescription for dysmenorrhoea: rejected by French drugs agency (Regulation)

p.177
A wise decision

Sildenafil and pulmonary hypertension in children (New Indication)

p.178
First, do no harm

Topical fluticasone for infants from 3 months of age (New Indication)

p.179
Inadequate assessment

Prescrire's comments

p.179
Fluticasone and infants : a poor example

Amlodipine + aliskiren (Combination)

p.180
Still no evidence that aliskiren reduces morbidity or mortality

Naproxcinod (Application Withdrawn)

p.180
No authorisation in the European Union

Pioglitazone: European approval maintained despite the acknowledged risks (Harms)

p.181
Chaotic regulation

Adverse Effects


Calcium channel blockers + macrolides: elderly patients hospitalised for low blood pressure

p.182
Avoid erythromycin and clarithromycin

Free  Domperidone: ventricular arrhythmia and sudden death

p.183
Do not use

Alcohol-based hand sanitizers: severe intoxication in children

p.184
Keep out of reach

NSAIDs: miscarriage (continued)

p.185
NSAIDs should not be used at any time during pregnancy

Vitamin E and prostate cancer

p.185
Unfavourable harm-benefit balance

Fluoroquinolones and tendon disorders: even after single-dose therapy

p.185
3 times more reports involved pefloxacin

Reviews


Paracetamol during pregnancy: no particular danger for the child

p.186-190

Paracetamol exposure in utero or during infancy: no increase in asthma

p.188-189

Outlook


Free  Corporate influence over clinical research: considering the alternatives

p.191-194
Funding drug research independent of drug companies: a pipe dream or a public health necessity?

Free  The exorbitant price of cancer drugs

p.195
No correlation with therapeutic benefits

Masthead


Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe